Prostate cancer is one of the most common cancers in men, it may cause no signs or symptoms in its early stages and
usually close to prostatitis or benign prostatic hyperplasia (BPH). Prostate cancer is higher risk in aging men, in order to not miss the initial stage of cancer men should examine prostate cancer screening at least once a year.
Prostate Cancer Screening CEC/CTC is peripheral blood CEC/CTC detection by Liquid biopsy technique, it is secondary screening of prostate cancer after PSA testing in patients with PSA 4-20 ng/ml. CEC/CTC is a biomarker that can be detected in earliest stage of prostate cancer and able to distinguish between non-aggressive and aggressive disease.
CEC (Circulating Endothelial Cells) are shed directly from growing tumors’ vessels into the host circulation since tumors as small as 1-2 mm. during the metastasis. It is an early biomarker of prostate cancer that can be derived into peripheral blood and can identify the initial stage of prostate cancer.
CTC (Circulating Tumor Cells) are shed directly from tumor cells. It is an early biomarker of prostate cancer that can be derived into peripheral blood in early stage of cancer as well however it is later than CEC.
The CEC/CTC discovery in blood circulation can indicate the initial stage of prostate cancer and can identify non-cancer people from those who have an aggressive prostate cancer in group of PSA 4-20 ng/ml that can be safe men from undetectable cancer and unnecessary biopsy.
N Health is ready to provide service Prostate Cancer Screening Test (CEC/CTC) according to the following list
*This operation schedule is for the test performed at N Health head quarter, Bangkok.
**Above Turnaround time does not include logistic time. For BDMS network hospitals, Please contact N Health laboratory located at your hospitals. BACK